COVID-19 Impact on Global Pharmaceutical Excipients Market:
The COVID-19 pandemic had a significant impact on the pharma industry. Lockdowns imposed in the wake of the outbreak disrupted the supply of raw materials from manufacturing hubs such as India and China. This slowed drug development and manufacturing, with severe impacts on companies that relied heavily on outsourcing. The entire pharmaceutical ecosystem was disrupted initially. Moreover, regulatory authorities also had to reframe and construct new laws to ensure maximum patient safety after drug consumption.
The end of the lockdowns saw the pharma industry gaining momentum, especially given the demand for drugs such as hydroxychloroquine and Remdesivir, which showed positive results against COVID-19. The increasing demand for these drugs drove revenue growth for some companies. The above mentioned factors suggest that the Covid-19 impact on the pharmaceutical excipients market is negligible as it is the starting material in manufacturing of pharmaceutical drugs.
Expected Revenue Growth:
The pharmaceutical excipients market is projected to reach USD 10.6 billion by 2026 from USD 7.9 billion in 2021, at a CAGR of 5.8% during the forecast period. The overall growth of the pharmaceutical excipients market is largely driven by the growing pharmaceuticals market, advancements in functional excipients, and the growing generics market.
Download PDF Brochure@
Growth Boosting Factors:
The rapidly growing biopharmaceuticals sector will also influence market growth for pharmaceutical excipients. However, the increasing regulatory stringency regarding the approval of drugs and excipients along with the cost and time-intensive drug development process are expected to restrain the growth of this market during the forecast period.
Global Key Players:
The global pharmaceutical excipients consist of a large number of leading market players based in developed countries. The prominent players in this market are Ashland Global Holdings (US), BASF SE (Germany), DuPont (US), Roquette Feres (France), Evonik Industries AG (Germany), Associated British Foods (UK), Archer Daniels Midland Company (US), Lubrizol Corporation (US), and Croda International (UK).
Other players in this market are Innophous Holdings (US), Kerry Group (Ireland), WACKER Chemie AG (Germany), Colorcon (US), DFE Pharma (Germany), JRS Pharma (Germany), and Air Liquide (France).
DuPont held the leading position in the pharmaceutical excipients market in 2020. DuPont offers a comprehensive portfolio of excipients, including rheology modifiers, tablet coatings, controlled release, stabilizers, solubilizers, binding agents, and masking agents. DuPont significantly invests in R&D activities to add innovative technologies and products to its portfolio, which, in turn, helps the company strengthen its presence in the pharmaceutical excipients market.
For instance, in 2019, DuPont invested USD 955 million in R&D activities. With a strong portfolio of pharmaceutical excipients and a focus on developing innovative products, the company is likely to maintain its strong position in this market in the coming years. Moreover, the company has a strong global presence and distribution network, with subsidiaries in more than 160 countries. It is further expanding inorganically through acquisitions.
Roquette Feres held the second position in the global market. Roquette is a global manufacturer of pharmaceutical excipients. The company has strengthened its position in this market through market expansion activities and innovations. The company owns more than 5,000 patents and has around 300 employees dedicated to the R&D of novel solutions. Roquette is currently focusing on expanding its presence in emerging economies. In line with this, Roquette acquired Itacel, the excipient division of Blanver in Brazil.
Roquette also acquired a majority stake in the Lithuaniabased company, Amilina, a producer of starch and derivatives. While achieving expansion in high-growth international markets, the company also intends to expand its pharmaceutical excipients product portfolio with the launch of new specialty excipients for the pharmaceutical industry. In this regard, Roquette introduced Maize Starch IP/BP and Mannitol IP, which are used as fillers in the pharmaceutical industry. The company also launched three new excipient brands. For its future growth, Roquette intends to further strengthen its existing relationships with key customers by organizing customer meetings, field visits, and training sessions on proactive quality management regularly in order to understand company functionalities and product portfolios better.
Request Sample Pages@
Asia Pacific is expected to account for the highest CAGR for players operating in the Pharmaceutical Excipients market
The Asia Pacific is the fastest-growing and most dynamic pharmerging market globally, poised to be the most attractive regional market due to its large base of generic drug manufacturers. Several factors, such as the growing Asian scientific base (due to the establishment of R&D centers and manufacturing facilities by major players in recent years); growth in the Asian pharmaceutical markets and pharmaceutica manufacturing capabilities; and the large patient pool are contributing to the growth of the pharmaceutical excipients market in the APAC.